Immunogenicity and Safety of Heterologous Versus Homologous Prime-Boost Regimens With BBIBP-CorV and Ad26.COV2.S COVID-19 Vaccines: A Multicentric, Randomized, Observer-Blinded Non-inferiority Trial in Madagascar and Mozambique.
Saved in:
| Title: | Immunogenicity and Safety of Heterologous Versus Homologous Prime-Boost Regimens With BBIBP-CorV and Ad26.COV2.S COVID-19 Vaccines: A Multicentric, Randomized, Observer-Blinded Non-inferiority Trial in Madagascar and Mozambique. |
|---|---|
| Authors: | Ramgi P; Instituto Nacional de Saúde, Maputo, Mozambique., Siribie M; International Vaccine Institute, Seoul, Republic of Korea.; Burkina Institute of Global Health, Ouagadougou, Burkina Faso., Rakotozandrindrainy N; Madagascar Institute for Vaccine Research, University of Antananarivo, Antananarivo, Madagascar., Bule O; Instituto Nacional de Saúde, Maputo, Mozambique., Shrivastava H; International Vaccine Institute, Seoul, Republic of Korea., Chambule L; Instituto Nacional de Saúde, Maputo, Mozambique., Park EL; International Vaccine Institute, Seoul, Republic of Korea., Fernando C; Instituto Nacional de Saúde, Maputo, Mozambique., Boque J; Instituto Nacional de Saúde, Maputo, Mozambique., Macuiana R; Instituto Nacional de Saúde, Maputo, Mozambique., Razafimanantsoa R; Madagascar Institute for Vaccine Research, University of Antananarivo, Antananarivo, Madagascar., Rakotozandrindrainy N; Madagascar Institute for Vaccine Research, University of Antananarivo, Antananarivo, Madagascar., Razafindrabe TJL; Madagascar Institute for Vaccine Research, University of Antananarivo, Antananarivo, Madagascar., Rakotoarisoa AN; Madagascar Institute for Vaccine Research, University of Antananarivo, Antananarivo, Madagascar., Raminosoa TM; Madagascar Institute for Vaccine Research, University of Antananarivo, Antananarivo, Madagascar., Derandrainy HL; Madagascar Institute for Vaccine Research, University of Antananarivo, Antananarivo, Madagascar., Rakotoson MM; Madagascar Institute for Vaccine Research, University of Antananarivo, Antananarivo, Madagascar., de Silva CSS; Instituto Nacional de Saúde, Maputo, Mozambique., Mutombene M; Instituto Nacional de Saúde, Maputo, Mozambique., Massinga C; Instituto Nacional de Saúde, Maputo, Mozambique., Langa JP; Instituto Nacional de Saúde, Maputo, Mozambique., Guarnacci T; International Vaccine Institute, Seoul, Republic of Korea., Kang SSY; International Vaccine Institute, Seoul, Republic of Korea., Jo SK; International Vaccine Institute, Seoul, Republic of Korea., Jeon HJ; International Vaccine Institute, Seoul, Republic of Korea.; Madagascar Institute for Vaccine Research, University of Antananarivo, Antananarivo, Madagascar.; Department of Medicine, Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge, Cambridge, United Kingdom., Excler JL; International Vaccine Institute, Seoul, Republic of Korea., Yang Y; China National Biotec Group Company Limited, China., Wang S; China National Biotec Group Company Limited, China., Sugimoto JD; International Vaccine Institute, Seoul, Republic of Korea.; Department of Epidemiology, University of Washington, Seattle, Washington, USA., Yang JS; International Vaccine Institute, Seoul, Republic of Korea., Shim BS; International Vaccine Institute, Seoul, Republic of Korea., Binger T; International Vaccine Institute, Seoul, Republic of Korea., Capitine IU; Instituto Nacional de Saúde, Maputo, Mozambique., Aziz AB; International Vaccine Institute, Seoul, Republic of Korea., Park JY; International Vaccine Institute, Seoul, Republic of Korea., Kim DR; International Vaccine Institute, Seoul, Republic of Korea., Rakotozandrindrainy R; Madagascar Institute for Vaccine Research, University of Antananarivo, Antananarivo, Madagascar., Jani IV; Instituto Nacional de Saúde, Maputo, Mozambique., Tadesse BT; International Vaccine Institute, Seoul, Republic of Korea.; Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden.; Center for Innovative Drug Development and Therapeutic Trials for Africa, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia., Marks F; International Vaccine Institute, Seoul, Republic of Korea.; Madagascar Institute for Vaccine Research, University of Antananarivo, Antananarivo, Madagascar.; Department of Medicine, Cambridge Institute of Therapeutic Immunology and Infectious Disease, University of Cambridge, Cambridge, United Kingdom.; Heidelberg Institute of Global Health, University of Heidelberg, Heidelberg, Germany.; The Hong Kong Jockey Club Global Health Institute, Hong Kong Special Administrative Region, China. |
| Source: | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2025 Jul 22; Vol. 80 (12 Suppl 2), pp. S37-S46. |
| Publication Type: | Equivalence Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 9203213 Publication Model: Print Cited Medium: Internet ISSN: 1537-6591 (Electronic) Linking ISSN: 10584838 NLM ISO Abbreviation: Clin Infect Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1537-6591 |
|---|---|
| DOI: | 10.1093/cid/ciaf130 |
